Phaseline

Targets › CLEC12A

CLEC12A (C-type lectin domain family 12 member A): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 4 Phase 1; Oncology, Hematology; next expected readout Apr 2028.

Myeloid inhibitory C-type lectin receptor that acts as a negative regulator of myeloid cell activation. Myeloid cell inhibition is required to limit pro-inflammatory pathways and protect against excessive inflammation (By similarity). (UniProt, Q5QGZ9)

Open in Phaseline: the race on CLEC12A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Memorial Sloan Kettering Cancer CenterADCLEC.syn1 CAR T cells
CAR-T cell therapy targeting CLEC12A
CLEC12APhase 1Acute Myeloid LeukemiaApr 2028
ARCE TherapeuticsARD103
anti-CLL-1 CAR-T cell therapy
CLEC12APhase 1Acute Myeloid Leukemia, in RelapseOct 2028
Celyad OncologyCYAD-02
CAR-T cell therapy targeting CLEC12A
CLEC12APhase 1Acute Myeloid LeukemiaFeb 2035
Baylor College of MedicineCLL-1.CAR T cells
CAR-T cells targeting CLL-1 antigen
CLEC12APhase 1Acute Myeloid LeukemiaJul 2038

Conditions

Acute Myeloid Leukemia (3) Acute Myeloid Leukemia, in Relapse (1)

Modalities

mixed (2), other (2)

Companies

Celyad Oncology (1) ARCE Therapeutics (1) Memorial Sloan Kettering Cancer Center (1) Baylor College of Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.